article thumbnail

CancerVar: A New Bioinformatics Tool Developed for Clinical Interpretation of Cancer Mutations

XTalks

Millions of somatic cancer variants have been identified due to precision medicine and next-generation sequencing (NGS). On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation).

article thumbnail

March 6, 2024: In This Week’s PCT Grand Rounds, Public-Private Partnerships in Health AI

Rethinking Clinical Trials

Pencina is a professor of biostatistics and bioinformatics and the vice dean for data science in the Duke University School of Medicine. .” The Grand Rounds session will be held on Friday, March 8, 2024, at 1:00 pm eastern. Join the online meeting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

February 19, 2024: Virtual Monitoring in Decentralized Trials, in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

Hernandez is the executive director of the Duke Clinical Research Institute (DCRI) and professor of medicine and vice dean in the Duke University School of Medicine. He also serves as co-principal investigator of the NIH Pragmatic Trials Collaboratory Coordinating Center. Join the online meeting.

Trials 135
article thumbnail

Absci and M2GEN partner to expedite cancer drug development

Pharmaceutical Technology

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

article thumbnail

February 21, 2024: In This Week’s PCT Grand Rounds, Virtual Monitoring in Decentralized Clinical Trials

Rethinking Clinical Trials

Hernandez is the executive director of the Duke Clinical Research Institute (DCRI) and professor of medicine and vice dean in the Duke University School of Medicine. He also serves as co-principal investigator of the NIH Pragmatic Trials Collaboratory Coordinating Center. Join the online meeting.

article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. At that time, we thought this would be the holy grail for medicine. Now, however, the field is changing with respect to genomic medicine.

Genome 119
article thumbnail

M2GEN partners with Zephyr AI to identify treatments for cancer patients

Pharmaceutical Technology

Oncology-focused bioinformatics firm M2GEN has entered a multi-year strategic collaboration with Zephyr AI to identify treatments and cures for cancer patients. This partnership not only holds the potential to chart a new era of drug discovery and precision medicine but to save innumerable lives.”